FDG-PET fits into an Alzheimer's workup as a selective follow-up scan used when history, exams, and brain structure imaging leave the cause of decline uncertain. It maps where brain cells are underactive and helps separate Alzheimer's from other dementias, but it does not by itself prove Alzheimer's pathology.
FDG-PET means fluorodeoxyglucose positron emission tomography. The scan measures regional brain glucose metabolism as a marker of synaptic activity, according to the Alzheimer's Association Workgroup in its revised 2024 Alzheimer's criteria. Doctors read the pattern of low metabolism, not a single number, and place it alongside clinical findings.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does the scan show?
- When is it ordered?
- How does it separate Alzheimer's from look-alikes?
- What are its limits?
- Will insurance cover it?
What does the scan show?
In Alzheimer's disease, FDG-PET typically shows bilateral symmetric low metabolism in temporoparietal cortex, posterior cingulate, and precuneus. The ACR-ASNR practice parameter describes this temporoparietal and posterior cingulate pattern as characteristic of Alzheimer's.
The Workgroup classifies FDG-PET as an "N" marker of neurodegeneration or injury. That makes it different from Core amyloid and tau tests. It shows downstream injury rather than plaques or tangles themselves.
When is it ordered?
FDG-PET comes after history, cognitive testing, and structural MRI or CT. The Alzheimer's Association describes it as a selective step when decline remains unexplained after specialist evaluation.
It is not a routine screening test. Current procedure guidance recommends it in two main situations, according to the SNMMI/EANM authors in their 2024 procedure standard. Those situations are support for early Alzheimer's diagnosis in mild cognitive impairment and differential diagnosis among Alzheimer's, frontotemporal degeneration, and Lewy-body disease.
- Ongoing memory or thinking changes despite normal or unclear MRI
- Overlapping symptoms where frontotemporal or Lewy-body dementia is possible
- Mild cognitive impairment where an injury pattern would change next steps
How does it separate Alzheimer's from look-alikes?
The value is comparison. Frontotemporal degeneration favors frontal and anterior temporal low metabolism.
Dementia with Lewy bodies favors occipital low metabolism with sparing of the posterior cingulate. Alzheimer's shows the opposite emphasis, with posterior temporoparietal and posterior cingulate involvement. That contrast helps explain why one scan can redirect a diagnosis from Alzheimer's toward another cause, or strengthen confidence in Alzheimer's.
What are its limits?
FDG-PET shows injury patterns but does not directly detect amyloid plaques. The Alzheimer's Association Workgroup states this limit in its 2024 criteria update. A scan alone therefore cannot establish Alzheimer's pathology.
Doctors pair it with amyloid PET, spinal-fluid testing, or validated p-tau217 blood testing when pathology confirmation matters. An AD-like FDG-PET pattern raises confidence and points to which confirmatory test is worth doing. That sequence matters before disease-modifying therapy, where amyloid confirmation is required.
Will insurance cover it?
Medicare coverage for dementia is narrow. Coverage applies for differential diagnosis of frontotemporal dementia versus Alzheimer's disease with documented six-month cognitive decline, or in a CMS-approved trial, under Medicare's PET coverage rule.
Families facing an unclear diagnosis can ask the specialist whether the case meets that distinction, whether a trial is available, and what the confirmatory amyloid test would add. For unclear dementia, an AD-like pattern can redirect referral, prognosis counseling, and test selection.





